Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MacroGenics
Biotech
MacroGenics pauses work on ADC pending mature survival data
MacroGenics has paused investment in additional opportunities for the ADC until it has updated data from a phase 2 monotherapy prostate cancer trial.
Nick Paul Taylor
Nov 6, 2024 4:44am
Biogen boosts C-suite with BMS vet—Chutes & Ladders
Nov 1, 2024 8:30am
MacroGenics' stock crashes after 5 deaths in ADC trial
May 10, 2024 6:00am
AbbVie drops MacroGenics-partnered ADC in light of early data
Mar 8, 2024 8:20am
Synaffix, MacroGenics crack open ADC pact, tack on $2.2B to deal
Mar 14, 2023 10:30am
Gilead offers $1.76B for option to MacroGenics' bispecific
Oct 17, 2022 11:00am
